Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.
Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer.
Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018.
The time is right for emerging UK medtech firm Locate Therapeutics, a company developing technology that could improve the way impending cell and gene therapies are delivered to patients.
Privately held Vaximm is seeking investment for its clinical pipeline that includes cancer vaccine VMX01, which is in Phase II as a monotherapy and due to start clinical trials next year in combination with Merck KGaA and Pfizer's PD-L1 inhibitor, Bavencio.
With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.